NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $3.03 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.03 0.00 (0.00%) As of 05/22/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nkarta Stock (NASDAQ:NKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nkarta alerts:Sign Up Key Stats Today's Range$3.01▼$3.2250-Day Range$2.00▼$3.4952-Week Range$1.63▼$3.65Volume356,284 shsAverage Volume818,309 shsMarket Capitalization$216.78 millionP/E RatioN/ADividend YieldN/APrice Target$10.75Consensus RatingModerate Buy Company Overview Nkarta, Inc. is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors. Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies. Additional pipeline candidates include NKX101, targeting acute myeloid leukemia, and a series of discovery-stage assets directed against solid tumor antigens. By combining a renewable NK cell source with scalable manufacturing processes, Nkarta seeks to deliver standardized, “off-the-shelf” treatments that can be administered without the delays and logistical complexities associated with patient-derived cell therapies. Founded by a team of immunotherapy and cell therapy experts, Nkarta is headquartered in South San Francisco, California. The company conducts its clinical trials across multiple sites in the United States and collaborates with academic institutions to advance its research. Nkarta’s leadership team is led by President and Chief Executive Officer James G. Joyce, Ph.D., who brings experience from prior senior roles in cell therapy development and commercialization. As a Nasdaq-listed company (NKTX), Nkarta continues to focus on accelerating clinical development, optimizing manufacturing scale-up and establishing strategic partnerships to broaden access to its NK cell therapy platforms. Through ongoing research and clinical studies, the company aims to establish new standards in off-the-shelf cell-based immunotherapies for patients with high-unmet-need cancers.AI Generated. May Contain Errors. Read More Nkarta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreNKTX MarketRank™: Nkarta scored higher than 78% of companies evaluated by MarketBeat, and ranked 156th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingNkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNkarta has a consensus price target of $10.75, representing about 254.8% upside from its current price of $3.03.Amount of Analyst CoverageNkarta has only been the subject of 4 research reports in the past 90 days.Read more about Nkarta's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nkarta are expected to grow in the coming year, from ($1.50) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.07% of the float of Nkarta has been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nkarta has recently decreased by 2.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. News and Social Media3.3 / 5News SentimentN/A News SentimentNkarta has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nkarta this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows10 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have not sold or bought any company stock.Percentage Held by Insiders8.40% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTX Stock News HeadlinesNkarta Inc Ordinary Shares NKTXMay 16, 2026 | morningstar.comMHere's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn SituationMay 14, 2026 | finance.yahoo.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 23 at 1:00 AM | Brownstone Research (Ad)Nkarta's (NKTX) "Buy" Rating Reaffirmed at Needham & Company LLCMay 14, 2026 | americanbankingnews.comNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)April 23, 2026 | theglobeandmail.comNkarta rises on FDA agreement for amended trial protocolApril 16, 2026 | msn.comNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersApril 15, 2026 | globenewswire.comSee More Headlines NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $1.85 at the beginning of 2026. Since then, NKTX stock has increased by 63.8% and is now trading at $3.03. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) announced its earnings results on Tuesday, May, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. When did Nkarta IPO? Nkarta (NKTX) raised $231 million in an initial public offering on Friday, July 10th 2020. The company issued 14,000,000 shares at a price of $16.00-$17.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Top institutional investors of Nkarta include Renaissance Technologies LLC (2.42%), Dimensional Fund Advisors LP (0.49%), Rangeley Capital LLC (0.10%) and Bank of America Corp DE (0.07%). Insiders that own company stock include Paul J Hastings, David Shook, Nadir Mahmood, James Trager and Alicia J Hager. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings5/12/2026Today5/23/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NKTX's financial health is in the Green zone, according to TradeSmith. NKTX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year Founded2015Price Target and Rating Average Price Target for Nkarta$10.75 High Price Target$12.00 Low Price Target$9.00 Potential Upside/Downside+254.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$104.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.90% Return on Assets-24.20% Debt Debt-to-Equity RatioN/A Current Ratio12.96 Quick Ratio12.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.00 per share Price / Book0.76Miscellaneous Outstanding Shares71,545,000Free Float65,535,000Market Cap$216.78 million OptionableOptionable Beta0.88 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:NKTX) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
